Axonyx’ Phenserine Could Be First Alzheimer’s Agent Targeting Beta-Amyloid Plaques To Reach FDA

Phase III trials for the acetylcholinesterase inhibitor are expected to complete in December 2004. Beta-amyloid is a primary therapeutic target as companies race to develop disease-modifying therapies that go beyond the symptom relief provided by current drugs. Statins and NSAIDs are also being examined for their potential to alter the course of AD.